Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
Jason Chesney(University of Louisville Hospital), Amod A. Sarnaik(Moffitt Cancer Center)
Cited by 305
Related Papers
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
|Journal of Clinical Oncology|2021|431
High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers.
|PubMed|2002|326
6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation of p27
|Cell Death and Disease|2014|204